Eric Viaud
Chief Executive Officer at Gene Signal International SA
Profile
Eric Viaud is the founder of Gene Signal SAS, founded in 2000, where he holds the title of Chairman & Chief Executive Officer.
He is also the founder of Gene Signal International SA, founded in 2010, where he holds the title of Chairman & Chief Executive Officer.
Currently, Mr. Viaud is the Chief Executive Officer at Société Petroliere du Bec d'Ambes.
He is also the Chairman at Arterial Remodelling Technologies SA since 2009.
Additionally, he is a Director at Aterovax SA since 2006.
In his former positions, Mr. Viaud worked as a Principal at Astra Zeneca Holding France SAS, BASF France SAS, and Medtronic France SAS.
Mr. Viaud graduated from Université de Bordeaux.
Eric Viaud active positions
Companies | Position | Start |
---|---|---|
Arterial Remodelling Technologies SA
Arterial Remodelling Technologies SA Pharmaceuticals: MajorHealth Technology Arterial Remodelling Technologies SA develops bioresorbable peripheral and coronary polymer stents. Its products includes ART PBS scaffold, procedure and Clinical data. The company was founded by Antoine Lafont, Michel Vert and J. Frederick Cornhill in 2001 and is headquartered in Paris, France. | Chairman | 2009-11-17 |
Gene Signal SAS
Gene Signal SAS Pharmaceuticals: GenericHealth Technology Gene Signal is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role. The company's innovative therapies use precisely targeted angiogenic (inducing vascular growth) or angiostatic (inhibiting vascular growth) agents, derived from genes that are exclusively involved with the angiogenesis process . The firm's therapies aim to provide a more targeted alternative to existing solutions like Vascular Endothelial Growth Factors which impact other physiological phenomena in addition to angiogenesis. Gene Signal's targeted therapies represents a novel, next-generation approach to the management of angiogenesis based conditions and offer the potential to improve treatment options for concerned patients. Founded in 2000, Gene Signal has assembled an strong leadership team that includes scientific, medical, regulatory, and business professionals with successful track records in developing and bringing to market state of the art drugs. Gene Signal continues to develop its angiogenesis modulating technology and has built a significant intellectual property portfolio, as well as a robust clinical and preclinical pipeline. | Chief Executive Officer | 1999-12-31 |
Gene Signal International SA
Gene Signal International SA Pharmaceuticals: MajorHealth Technology Gene Signal International SA engages in the development of drugs to manage angiogenesis based conditions. It is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role. The company was founded by Eric Viaud, Salman Al-Mahmood, and Eric Thorin in 2000 and is headquartered in Lausanne, Switzerland. | Chief Executive Officer | 1999-12-31 |
Aterovax SA
Aterovax SA Medical/Nursing ServicesHealth Services Aterovax SA develops in vitro diagnostic products for the management and assessment of cardiovascular diseases. Its products include diagnostic blood tests for determining and measuring activity of the cardiovascular biomarkers secretory phospholipase A2 (sPLA2) and secretory phospholipase A2-IIA (sPLA2-IIA) which provide physicians clinical information about the presence of a destabilized atherosclerotic plaque. The company was founded by Alain Tedgui, Ziad Mallat, Philippe Gabriel Steg, Joelle Benessiano and Jean-Marie Freyssinet on June 29, 2006 and is headquartered in Paris, France. | Director/Board Member | 2006-08-15 |
Société Petroliere du Bec d'Ambes
Société Petroliere du Bec d'Ambes Miscellaneous Commercial ServicesCommercial Services Société Petroliere du Bec d'Ambes provides refrigerated storage facility services. The company is headquartered in Carbon-Blanc, France. | Chief Executive Officer | - |
Former positions of Eric Viaud
Companies | Position | End |
---|---|---|
BASF France SAS
BASF France SAS Chemicals: Major DiversifiedProcess Industries BASF France manufactures and markets coating products. The company is headquartered in Levallois-Perret, France. | Corporate Officer/Principal | - |
Medtronic France SAS
Medtronic France SAS Medical/Nursing ServicesHealth Services Medtronic France SAS provides medical equipment and medical technology services. The company was founded by Earl Bakken and Palmer Hermundslie in 1949 and is headquartered in Boulogne-Billancourt, France. | Corporate Officer/Principal | - |
Astra Zeneca Holding France SAS
Astra Zeneca Holding France SAS Pharmaceuticals: MajorHealth Technology Astra Zeneca Holding France SAS operates as a holding firm with interest in pharmaceuticals. The company was founded in 1994 and is headquartered in Rueil-Malmaison, France. | Corporate Officer/Principal | - |
Training of Eric Viaud
Université de Bordeaux | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 8 |
---|---|
Arterial Remodelling Technologies SA
Arterial Remodelling Technologies SA Pharmaceuticals: MajorHealth Technology Arterial Remodelling Technologies SA develops bioresorbable peripheral and coronary polymer stents. Its products includes ART PBS scaffold, procedure and Clinical data. The company was founded by Antoine Lafont, Michel Vert and J. Frederick Cornhill in 2001 and is headquartered in Paris, France. | Health Technology |
Gene Signal SAS
Gene Signal SAS Pharmaceuticals: GenericHealth Technology Gene Signal is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role. The company's innovative therapies use precisely targeted angiogenic (inducing vascular growth) or angiostatic (inhibiting vascular growth) agents, derived from genes that are exclusively involved with the angiogenesis process . The firm's therapies aim to provide a more targeted alternative to existing solutions like Vascular Endothelial Growth Factors which impact other physiological phenomena in addition to angiogenesis. Gene Signal's targeted therapies represents a novel, next-generation approach to the management of angiogenesis based conditions and offer the potential to improve treatment options for concerned patients. Founded in 2000, Gene Signal has assembled an strong leadership team that includes scientific, medical, regulatory, and business professionals with successful track records in developing and bringing to market state of the art drugs. Gene Signal continues to develop its angiogenesis modulating technology and has built a significant intellectual property portfolio, as well as a robust clinical and preclinical pipeline. | Health Technology |
Gene Signal International SA
Gene Signal International SA Pharmaceuticals: MajorHealth Technology Gene Signal International SA engages in the development of drugs to manage angiogenesis based conditions. It is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role. The company was founded by Eric Viaud, Salman Al-Mahmood, and Eric Thorin in 2000 and is headquartered in Lausanne, Switzerland. | Health Technology |
Aterovax SA
Aterovax SA Medical/Nursing ServicesHealth Services Aterovax SA develops in vitro diagnostic products for the management and assessment of cardiovascular diseases. Its products include diagnostic blood tests for determining and measuring activity of the cardiovascular biomarkers secretory phospholipase A2 (sPLA2) and secretory phospholipase A2-IIA (sPLA2-IIA) which provide physicians clinical information about the presence of a destabilized atherosclerotic plaque. The company was founded by Alain Tedgui, Ziad Mallat, Philippe Gabriel Steg, Joelle Benessiano and Jean-Marie Freyssinet on June 29, 2006 and is headquartered in Paris, France. | Health Services |
Astra Zeneca Holding France SAS
Astra Zeneca Holding France SAS Pharmaceuticals: MajorHealth Technology Astra Zeneca Holding France SAS operates as a holding firm with interest in pharmaceuticals. The company was founded in 1994 and is headquartered in Rueil-Malmaison, France. | Health Technology |
BASF France SAS
BASF France SAS Chemicals: Major DiversifiedProcess Industries BASF France manufactures and markets coating products. The company is headquartered in Levallois-Perret, France. | Process Industries |
Medtronic France SAS
Medtronic France SAS Medical/Nursing ServicesHealth Services Medtronic France SAS provides medical equipment and medical technology services. The company was founded by Earl Bakken and Palmer Hermundslie in 1949 and is headquartered in Boulogne-Billancourt, France. | Health Services |
Société Petroliere du Bec d'Ambes
Société Petroliere du Bec d'Ambes Miscellaneous Commercial ServicesCommercial Services Société Petroliere du Bec d'Ambes provides refrigerated storage facility services. The company is headquartered in Carbon-Blanc, France. | Commercial Services |
- Stock Market
- Insiders
- Eric Viaud